by Paul McIntosh | Sep 6, 2023 | 2023, Press Releases
ABERDEEN 6 SEPTEMBER 2023. NovaBiotics, the clinical-stage biotechnology company announces the appointment of Dr Trevor Phillips to its board as Non-Executive Director. Trevor is a biotechnology leader who previously held board and C-level roles in pharma and Biotech...
by Paul McIntosh | Apr 21, 2022 | 2022, Press Releases
New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in community acquired pneumonia and also data demonstrate the in vitro safety profile, fungal cell specificity and potential of NP339 in respiratory...
by Paul McIntosh | Dec 8, 2021 | 2021, Press Releases
NovaBiotics’ NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias Aberdeen, December 8, 2021. NovaBiotics Ltd, a privately held clinical stage company developing...
by novabioticsadm1n | Nov 1, 2021 | 2021, Press Releases
by Paul McIntosh | Oct 29, 2021 | 2021, Press Releases | 0 comments Highlights new insights into cysteamine’s mechanism of action against Pseudomonas aeruginosa and Burkholderia cenocepacia, further supporting cysteamine’s potential as an antimicrobial intervention in...
by novabioticsadm1n | Oct 5, 2021 | 2021, Press Releases
Highlights potential of novel antifungal’s immune-based approach to inhibit fungal pathogens Aberdeen, October 5, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases,...
by novabioticsadm1n | Sep 23, 2021 | 2021, Press Releases
This new data further supports the potential of NM001 against the most clinically challenging bacterial pathogens, including Pseudomonas aeruginosa, in respiratory disease. NM001 is a registration study-ready candidate intervention (acute use) for pulmonary...
Recent Comments